Depomed in another deal for metformin extended release, with Boehringer Ingelheim
This article was originally published in Scrip
Executive Summary
Depomed has licensed to Boehringer Ingelheim worldwide rights to its Acuform gastric retentive drug delivery technology for the development and commercialisation of certain fixed dose combination products which include extended-release metformin and other proprietary Boehringer compound(s) in development for type 2 diabetes.